The proposed guideline will replace ‘points to consider on the evaluation of medicinal products for the treatment of irritable bowel syndrome CPMP/EWP/785/97’. Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder in which abdominal discomfort or pain is associated with changes in bowel habits, stool consistency and other features of disordered defecation.
|Consultation start date||08/06/2012|
|Consultation end date||31/08/2012|
|Email address for email@example.com|